Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Theratechnologies Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action active for this portfolio. This action is assigned to 1 distinct examiner, which suggests a concentrated prosecution effort at this stage.
The portfolio's activity is restricted to 1 distinct art unit, aligning with the 1 distinct examiner assigned to the case. AMBER D STEELE is the busiest examiner identified in the data, currently managing 1 busiest examiner pending office action. As the total number of pending office actions is 1, AMBER D STEELE is responsible for all current examination tasks for the company.
For practitioners, this means that the prosecution strategy is focused on a single point of contact within the patent office. The presence of 1 distinct art unit indicates that the technical review is confined to one specific area of expertise. With 1 pending office action, the administrative complexity is low, and the interaction with AMBER D STEELE will be the primary factor in the portfolio's immediate progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17781653 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | STEELE, AMBER D | 1658 | §103Other | Final Rejection | 54d | Pending | Jun 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial